Nanospectra Biosciences

Focus: Nanospectra Biosciences is a Houston-based oncology biotech focused on laser-mediated tumor ablation using proprietary nanoparticle technology. The company operates in a highly specialized segment with a small clinical footprint.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Nanospectra Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow Nanospectra Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

AuroLase Therapy

Head and Neck Cancer

N/A

Clinical Trials (1)

NCT00848042Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck

N/A

Help build intelligence for Nanospectra Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering novel oncology modality (photothermal therapy) with differentiated mechanism versus conventional treatments
Focused pipeline in high-prevalence cancers (prostate, head/neck, lung) with multiple active clinical programs
Early-stage company with potential for meaningful equity upside if lead programs advance

Watch Out For

No marketed products or revenue generation—high operational risk with unknown cash runway and funding stability
Minimal published data (0 publications on record) and extremely limited clinical trial activity (4 trials total, phase status unclear) suggest early developmental stage
Zero active job openings signals contraction or potential financial constraints limiting hiring and career mobility

Generated by Claude from Nanospectra Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

AuroShell particle infusion

Neoplasms of the Prostate

N/A

Clinical Trials (1)

NCT04240639An Extension Study MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue

N/A

AuroLase Therapy

Primary or Metastatic Lung Tumors

N/A

Clinical Trials (1)

NCT01679470Efficacy Study of AuroLase Therapy in Subjects With Primary and/or Metastatic Lung Tumors

N/A

AuroShell particle infusion

Neoplasms of the Prostate

N/A

Clinical Trials (1)

NCT02680535MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

4 pipeline

Marketed

Pipeline